McKinney J S, Fu X T, Swearingen C, Klohe E, Karr R W
Department of Immunology, G. D. Searle & Co., St. Louis, MO 63198.
J Immunol. 1994 Dec 15;153(12):5564-71.
The four members of the HLA-DR11 family of class II molecules vary only by three or fewer amino acids via dimorphisms among DR beta-chain residues 67, 71, and 86. However, they differ markedly in their abilities to induce proliferation of DR(alpha,beta 11101)-restricted, peptide-specific T cell clones. To dissect which DR11-variable residues, individually and in combination, mediate these functional differences, we used as APC transfectants expressing DR molecules with one of all possible permutations of DR11-variable sequences, including the four DR11 family members, and four additional DR11 variant mutants. The abilities of the wild-type or mutant molecules to present two distinct influenza peptide Ags, HA307-19 and HA128-45, to T cells was assessed in in vitro T cell proliferation assays. Of the naturally dimorphic DR11 positions, residue beta 71 variation significantly influenced the ability of DR11 molecules to present both peptides to DR(alpha,beta 11101)-restricted T cells. Residue beta 86 variation had relatively less influence than reported in several other DR and peptide systems. Residue beta 67 variation usually appeared irrelevant to T cell proliferation, but in two mutants led to unexpected T cell proliferation independent of nominal peptide Ag. Peptide binding, assessed by flow cytometry, was not found to be altered by any mutations that disrupted DR(alpha,beta 1*1101)-like presentation. These data indicate that residue beta 71 exerts a central role in influencing the functional differences among DR11 molecules, whereas the widely studied dimorphism of residue beta 86 is not as generally influential in DR11 as in other alleles.
II类分子HLA - DR11家族的四个成员,通过DRβ链第67、71和86位残基的双态性,彼此之间仅相差三个或更少的氨基酸。然而,它们在诱导DR(α,β11101)限制性、肽特异性T细胞克隆增殖的能力上却有显著差异。为了剖析哪些DR11可变残基单独或组合起来介导了这些功能差异,我们使用表达具有DR11可变序列所有可能排列之一的DR分子的APC转染细胞,这些排列包括四个DR11家族成员以及另外四个DR11变体突变体。在体外T细胞增殖试验中评估了野生型或突变型分子向T细胞呈递两种不同流感肽抗原HA307 - 19和HA128 - 45的能力。在天然双态的DR11位置中,β71位残基的变异显著影响DR11分子向DR(α,β11101)限制性T细胞呈递两种肽的能力。β86位残基的变异影响相对小于其他一些DR和肽系统中的报道。β67位残基的变异通常似乎与T细胞增殖无关,但在两个突变体中导致了与名义肽抗原无关的意外T细胞增殖。通过流式细胞术评估的肽结合情况,未发现因任何破坏类似DR(α,β1*1101)呈递的突变而改变。这些数据表明,β71位残基在影响DR11分子功能差异方面发挥核心作用,而广泛研究的β86位残基双态性在DR11中不像在其他等位基因中那样具有普遍影响力。